Visão Geral
Variação de preço das ações
24h
Atual
Mín
47.35
Máximo
47.41
Próximos Ganhos | 3 de nov. de 2026 |
|---|
Sentimento de Notícias
By Acuity
100%
0%
322 / 339 Ranking em Healthcare
Rigel Pharmaceuticals Inc Gráfico
O desempenho passado não é um indicador confiável de resultados futuros.
Notícias Relacionadas
11 de set. de 2026, 19:46 UTC
Rigel Pharmaceuticals is higher today, influenced by CPI data and speculation about potential Federal Reserve interest rate hikes. The stock remains near its one-month trading range.
Ler
10 de set. de 2026, 23:21 UTC
Rigel Pharmaceuticals Inc is rising in after-market trading, reversing a three-session decline. No specific news was identified to explain this price action.
Ler
8 de set. de 2026, 20:07 UTC
Rigel Pharmaceuticals Inc shares are lower today, continuing a decline since Friday. The stock saw notable volatility but remains above its 20-day moving average.
Ler
1 de set. de 2026, 20:08 UTC
Rigel Pharmaceuticals Inc shares are higher today, reflecting strong market performance and robust momentum above the 20-day moving average. No specific news was identified.
Ler
31 de ago. de 2026, 20:07 UTC
Rigel Pharmaceuticals is lower today as the market reacts to comments from Warsh at the Jackson Hole Economic Symposium regarding elevated inflation and potential rate hikes.
Ler
25 de ago. de 2026, 20:07 UTC
Rigel Pharmaceuticals shares are advancing, supported by easing Treasury yields and lower oil prices, despite pulling back from earlier session highs.
Ler
24 de ago. de 2026, 19:56 UTC
Rigel Pharmaceuticals Inc shares are lower today, with no specific news identified for the decline. The stock remains above its 20-day moving average.
Ler
21 de ago. de 2026, 19:36 UTC
Rigel Pharmaceuticals Inc is trading higher, despite pulling back from an earlier session peak. The stock remains above its 20-day moving average.
Ler
20 de ago. de 2026, 20:06 UTC
Rigel Pharmaceuticals Inc. shares are lower today, continuing a decline since Wednesday amid broader market pressures, though no specific news has been identified.
Ler
19 de ago. de 2026, 20:02 UTC
Rigel Pharmaceuticals Inc is trading higher amid strong market activity and high volume, reflecting increased investor interest since Tuesday's close.
Ler
18 de ago. de 2026, 22:01 UTC
Rigel Pharmaceuticals shares declined in after-market trading, dropping significantly amid broader market pressures from rising bond yields and inflation concerns.
Ler
17 de ago. de 2026, 20:06 UTC
Rigel Pharmaceuticals Inc. shares declined despite mixed analyst ratings updates. Piper Sandler raised its price target to $49, while H.C. Wainwright set it at $85.
Ler
14 de ago. de 2026, 20:06 UTC
HC Wainwright raised Rigel Pharmaceuticals' price target to $85, boosting investor sentiment. Shares are trading higher since Thursday's close amid mixed market conditions.
Ler
13 de ago. de 2026, 19:16 UTC
Rigel Pharmaceuticals shares decline following the launch of its breast cancer drug Veppanu, priced at $29,400 per month, amid safety concerns.
Ler
11 de ago. de 2026, 20:06 UTC
Rigel Pharmaceuticals Inc shares are higher in Tuesday's session, continuing gains from previous days amid routine fluctuations and no specific news driving the movement.
Ler
7 de ago. de 2026, 19:26 UTC
Rigel Pharmaceuticals reported EPS of $0.88, exceeding estimates. Revenue of $78.70 million also surpassed expectations, though analysts have mixed ratings on the stock.
Ler
6 de ago. de 2026, 20:06 UTC
Rigel Pharmaceuticals shares lower as the company in-licenses Veppanu for breast cancer treatment, projecting 2026 revenues of $285 million to $295 million.
Ler
5 de ago. de 2026, 20:02 UTC
Rigel Pharmaceuticals shares rise as the company reports Q2 EPS of $0.88, exceeding estimates, and raises full-year sales guidance to $285 million-$295 million.
Ler
4 de ago. de 2026, 23:01 UTC
Rigel Pharmaceuticals shares higher after reporting Q2 earnings of $0.88 and raising full-year sales guidance to $285 million to $295 million.
Ler
3 de ago. de 2026, 19:26 UTC
Rigel Pharmaceuticals Inc. is higher today, aligning with market trends as the S&P 500 and Nasdaq see gains amid improved investor sentiment.
Ler
31 de jul. de 2026, 19:41 UTC
Rigel Pharmaceuticals is lower today amid significant downward pressure in the Biotechnology sub-sector, despite a slight recovery from session lows.
Ler
30 de jul. de 2026, 19:29 UTC
Rigel Pharmaceuticals Inc shares are lower today amid unusual volatility, reaching a session low earlier after peaking shortly after the market opened.
Ler
29 de jul. de 2026, 19:47 UTC
Rigel Pharmaceuticals Inc. is trading higher Wednesday, pulling back from earlier session highs amid mixed performance across major U.S. indices ahead of the Fed's decision.
Ler
28 de jul. de 2026, 19:56 UTC
Rigel Pharmaceuticals shares are higher today as the company announced a conference call for its second quarter 2026 financial results on August 4.
Ler
27 de jul. de 2026, 16:16 UTC
Rigel Pharmaceuticals is higher during Monday's session, rebounding after six days of declines. The stock remains up since Friday's close amid broader market dynamics.
Ler
24 de jul. de 2026, 20:01 UTC
Rigel Pharmaceuticals Inc shares are higher today, recovering from earlier dips amid increased trading volume and broader market gains despite no specific news identified.
Ler
22 de jul. de 2026, 20:06 UTC
Rigel Pharmaceuticals Inc shares are lower Wednesday amid ongoing market uncertainty ahead of the Federal Reserve meeting, with no specific news driving the decline.
Ler
21 de jul. de 2026, 17:26 UTC
Rigel Pharmaceuticals Inc shares are higher, reflecting positive sentiment in the biotechnology sector amid broader market gains, particularly in technology stocks.
Ler
Comparação entre Pares
Variação de preço
Rigel Pharmaceuticals Inc Previsão
Consenso de Avaliação
By TipRanks
Compra Moderada
4 ratings
2
Comprar
2
Manter
0
Vender
Com base em 4 analistas que deram avaliações de ações para Rigel Pharmaceuticals Inc - Dist nos últimos 3 meses.
Sentimento
By Acuity
Sentimento de Notícias
Evidência Muito Forte de Tendência de Baixa
Volatilidade
Abaixo da média
Volume de Notícias (RCV)
Abaixo da média
Informação Financeira
$